speed in complex tasks. For example, one important constraint to reduce complexity is attention, the selection of a subset of the input data or a subset of potential outputs that focus on the most relevant options. Strategies are now being developed to operationalize 'attention' and other biologically based approaches, and transport them to intelligent devices.
And in a third essay, Buckholtz and Faigman bring in the law. After all, once the new brain-machine interfaces are in place, who is to blame when your prosthetic arm kills someone? These instances where we might look to the technology to find responsibility for our actions shade into cases where our better understanding of the neuroscience of behavior suggests neural sources for antisocial acts. We can blame murder on Ambien or Twinkies, on YYX chromosomes or on just being male. Where does responsibility fall, morally and legally, once we have more comprehensive explanations of violent behavior from neuroscience. How reliable is the use of neuroscience as evidence in court. Buckholtz and Faigman consider the difficulty of evaluating scientists' testimony as well as the use of fMRI or other biomarkers of lying, and the use of predictive constraints on individuals with neural correlates of antisocial behavior. Neuroscience, perhaps more than any other science, will become increasingly involved in deciding legal cases and policy. Buckholtz and Faigman offer some guidance to the issues that will be raised as this progresses.
In reading through these reviews, primers, and essays, it is clear that neuroscience is now a major player in medicine and the development of new learning and legal methods. At one time, a 'moon shot' meant that your project was ambitious but had almost no chance of succeeding. But, of course, we did land on the moon, and neuroscience has now reached a level of maturity and progress where a 'moon shot' for neuroscience should mean just that, a massive moonlanding level of investment to bring the fruits of neuroscience, many on display in this special issue, to society. By its very nature, views on a suicide in the state of depression depend on people's philosophy and outlook on life. Reactions range from the view that depression is a deadly disease like cancer and suicide is just its fatal symptom, through to the description of suicide as an act of free will designed to escape an unbearable situation. Charities like the Samaritans and Mind have warned that the latter view, if propagated in the media, may trigger further suicides, as may the reporting of excessive detail of the ways and means employed in the act. However, with the global media competing over this exceptional story, this advice was frequently neglected in the reporting.
In the wake of Williams' death, attention turned to the broader issues of depression, which is widespread but still widely misunderstood. Major depression, according to a definition from US psychiatrist Allen Frances,
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Depression has become one of the biggest health problems globally, but in certain places more than in others, suggesting cultural as well as biological causes. Neuroscientists are only beginning to understand underlying processes and to develop effective treatments for those cases where conventional psychotherapy and drugs fail. Michael Gross reports.
Silver linings for patients with depression?
Melancholic mind: The artist Edvard Munch (1863 Munch ( -1944 "must be dense (i.e., present for most of the day, almost every day); must last at least a few weeks; and must be severe enough to cause clinically significant impairment" (quoted from Essentials of Psychiatric Diagnosis). That sounds terrifying enough to justify an urgent call to a medical practitioner, but sufferers who would need medical help are still facing unhelpful comments like "just get over it" from people who fail to understand that mental illness is just as real as physical disorders.
Such misconceptions may be part of the reason why only a minority of sufferers are actually getting the medical help they require. The new president of the UK's Royal College of Psychiatrists, Simon Wessely, told The Guardian newspaper that less than a third of UK patients with depression receive any treatment at all. While the figure for schizophrenia stands at two thirds, Wessely argued that there would be a public outcry if similar statistics applied to cancer. While the UK government has pledged "parity of esteem" for mental and physical healthcare, Wessely pointed out that the realisation of that promise would require funds to be shifted from acute provision to mental health, and he expressed doubt as to whether the necessary political consensus was there to achieve that.
Elsewhere, there are similar problems. A recent study in Germany found that patients with mild depression may get medicated too readily, but of those with severe symptoms, three quarters don't get the help they need. On the other hand, the study also found that depression is more often diagnosed in the wealthier and sunnier south of the country. Is it because those blessed lands are fertile ground for doctors' surgeries, or do residents struggle to keep up with the happiness of their neighbours?
Causes
Depression is a complex disorder, and one of its complexities is that we don't really understand where it comes from. There are obvious, "depressing" life events that can make people gloomy for a week or two, but such acute-phase sadness should be regarded as a separate and unrelated phenomenon -even though Allen Frances has warned that the latest edition of the Diagnostic and Statistical Manual, DSM-5, makes the mistake of blurring the boundaries between the two (Curr. Biol. (2013) 23, R295-R298).
So, if there is no acute reason to be gloomy, and if Western societies supposedly are providing wealth and happiness for most of their citizens, why has depression reached epidemic proportions?
In his book The Selfish Capitalist, British psychologist Oliver James has argued that the root of the problem lies in the combination of "affluenza" -the infectious materialist desires beyond the reasonable quest for the necessary and useful -and the rapidly growing inequality which blocks most people from achieving the kind of affluence they have been taught to aspire to. The combined effects of consumerism creating unreasonable desires and inequality frustrating them is, according to James, a likely cause why "selfish capitalist" countries like the UK and the US now have mental illness rates above 20%, twice as high as in 1980, and also twice as high as those observed today in less selfish economies such as those of continental Europe.
James's analysis builds on Erich Fromm's ideas, who in the 1950s postulated that the emphasis on Having rather than Being in Western society was the symptom of a sick society that would inevitably produce mental disorders. In Fromm's day, there was very little scientific evidence to back up such theories, but the large-scale adoption of Thatcherite economics in the Englishspeaking world since the 1980s constitutes an experiment whose unwilling participant may provide significant material for such analyses. Moreover, James lists a number of psychological studies conducted from the 1990s onwards, which have backed Fromm's hypothesis that rampant materialism is bad for your mental health.
While it is difficult to compare mental health statistics between countries and across cultural boundaries, James based his analysis on a major WHO investigation including 25 countries and using the Diagnostic and Statistical Manual of Mental Health (DSM) criteria as the uniform basis in all countries. James concludes that many stress factors of modern life, from city-dwelling through to the disintegration of traditional bonds in family, religion and society, contribute to the conditions that he prefers to call emotional distress rather than mental illness. These are shared between industrialised countries and may explain why three-quarters of the phenomena listed in the DSM are virtually unknown in pre-industrial societies.
For the differences between nations, however, James considers the most likely culprit to be the deregulated capitalism, which has been most fervently embraced in the English-speaking countries, where it has driven up inequality and competition in the labour market. Compared with 1980, the income of the average worker has stalled, but people have to compete much harder to find work and keep it. At the same time, an increasing amount of stress arises from the futile attempts to fulfil material desires created by the advertising industry.
Beyond these cultural and psychological factors, there are also neurobiological effects linked to depression, although it is difficult to establish whether they are causative or symptomatic. 
Therapy options
If Fromm and James are right and mental illness is predominantly a symptom of a sick society, then the therapy should target the very system we live in. Since the financial crisis started in 2008, protests from the Occupy movement and others have highlighted the very same problems arising from the increasing gap between the richest 1% and the struggling 99%.
However, while we are waiting for a landslide election result or revolution to change the fundamental credo of "selfish capitalist" countries, there is a large number of patients who urgently need medical help. There is no shortage of medication to lighten the mood of patients with milder cases of depression, but it's the severe end of the spectrum that is causing concern. "The cruel paradox is that we are massively overmedicating people with mild depressive symptoms that will resolve on their own or with brief psychotherapy, while shamefully neglecting those who have severe depressions that desperately require more intense treatment," says Allen Frances.
As an inability to get out of bed and do something about one's problems is often an intrinsic part of the disorder, patients with severe depression may lose treatment opportunities by missing appointments or failing to comply with their treatment schedule. Shortage of psychotherapists may mean that patients who would benefit from "talking therapy" such as the widely approved "cognitive therapy" (a fixed-term course that teaches patients to focus on positive thoughts) don't get this kind of help and may have to resort to drugs instead.
Whether psychotherapy, drug therapy or a combination of both is the right answer remains a highly contentious issue. In a recent, large-scale, randomised clinical trial involving 452 patients with depression, Steven Hollon from Vanderbilt University at Nashville Tennessee, with colleagues from other institutions, found that combining drug treatment with cognitive therapy, compared with one or the other, improved the outcome significantly for one third of patients, while offering little benefit for the other two thirds (JAMA Psychiatry 2014, http://dx.doi.org/10.1001/ jamapsychiatry.2014.1054).
Previous smaller studies and metastudies based on them had failed to resolve the question of who is most likely to benefit from combination treatment. The study by Hollon and colleagues could clearly show that the advantage of combination therapy over drugs-only treatment is only detectable for severe, non-chronic depression.
The combined approach is already part of clinical practice for severe depression in the UK, but not in the US. With the results from this clinical trial it will now be easier to target the approach to those patients most likely to benefit.
In a significant number of patients, severe depression is resistant to both psychotherapeutic and drug treatment. For these cases, novel methods of stimulating the brain are offering a silver lining. One of the promising new approaches is transcranial magnetic stimulation (TMS). In 1993, while working at the National Institute of Mental Health (NIMH) in Washington, DC, Mark George discovered that daily application of TMS to the prefrontal lobe over several weeks could alleviate depression. Since then, George and others have worked to develop and test a well-defined methodology of applying TMS to treat depression. The method was approved by the While the method is already applied in the clinic, mostly in cases where repeated attempts at conventional therapy have failed, research into its benefits continues. In a recent randomised clinical trial involving suicidal inpatients at a military hospital, George's group, now at the Medical University of South Carolina at Charleston, USA, showed that the treatment is feasible and safe for this particularly vulnerable group of patients. However, the suicidal thoughts subsided almost as quickly in the placebo control group (given a sham treatment) as in the treatment group. None of the patients died from suicide in the six months after the treatment (Brain Stimulation (2014) 7, 421-431) .
Studying the long-term quality of life outcomes of patients with depression after TMS treatment, the group of Sarah "Holly" Lisanby at Duke University carried out a randomised, sham-controlled trial and found that the quality of life improvements after TMS compared to sham treatment were statistically significant and remained so at a follow-up investigation six months after the treatment (Brain Stimulation (2014) 7, 219-225) .
Other treatments that may be used in difficult cases include electroconvulsive therapy (ECT, formerly known as electroshock therapy) and deep brain stimulation, which involves implantation of electrodes to deliver electrical impulses to specific areas of the brain. Compared to these measures of last resort, TMS has the marked advantage of being non-invasive and free of major side effects.
Overall, the science of addressing the most difficult cases of depression is still very much in flux, as is our understanding of why so many people get depressed in the first place. Important discussions are to be had about how healthy or sane our Western culture is, where many millions aspire to the gilded lifestyle of celebrities, even if the very same celebrities are driven to despair.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk
John K. Tsotsos
Discoveries about the brain, its function and human behavior are being made at an amazing rate. This special issue is about how our increasing knowledge in neuroscience is fostering new applications and technologies. Perhaps more is known about the visual system of the brain than any other component, and more of the brain's cortical neurons are devoted to visual processing than any other task and thus this essay will focus on vision. The fact that we have successfully built cameras using inspiration from the structure and function of our eyes encourages us to attempt to re-create the rest of the visual system artificially. The quest to create artificial vision has now seen over a half-century of increasingly intense activity. Each discovery about human vision can be regarded as a hint or clue that might be helpful in developing a functioning artificial vision system. But there are far more experimental discoveries than useful clues. And how one translates these hints into real systems is also very important. At what level of abstraction should it apply? What mathematical formulation or computational construct best models the hint? How is the result evaluated with respect to its computational performance? What degree of faithfulness to those neurobiological and behavioral observations is most useful? There are no easy answers to such questions and success lies mainly with the intuition and innovation of the developer.
Suppose one could list all the hints and clues that might apply to the creation of a successful vision system, whether artificial or biological: let the largest oval in
Essays
Our ever-growing knowledge about the human brain and human behavior is opening doors to increasingly impressive technological achievements. This neurobiological inspiration has a significant history and involves almost equal parts neuroscience, computation and art. With a focus on the sense of vision, this essay presents a selective and highly condensed snapshot of the history of how neurobiology has inspired technological developments, pointing the way to where new inspirations may lead. Figure 1 represent all of these, each being one of the little blobs in light blue. What is the nature of these clues? Each is some characteristic or a truth about visual processing, such as, 'one needs to understand what is being seen, regardless of the direction from which it is viewed', or stated differently, 'perception needs to be invariant to viewpoint'. The number of such characteristics is very large and more examples will appear below. It is important to note that the complete set of hints is not yet known.
It's all about the constraints
It is also important to understand that not all experimental observations about vision are useful. We certainly do not need to include any diseases of the visual system or any characteristics of how our eyes and vision systems age in the development of artificial vision, although we can often learn about normal, healthy vision by understanding such failures. Each of these hints, clues and characteristics in a direct manner constrain the development of artificial vision. To illustrate what is meant by constrain here, suppose you wish to bake a cake. Before you lies the whole universe of possible cake designs, shapes, and so on. Choosing a round ten-inch cake pan will constrain the eventual outcome; the choice reduces the space of all possibilities that you faced to the smaller space of all round ten-inch cakes. Any subsequent decisions are then constrained by the round pan, and as more decisions are takenchocolate, three-layers, mocha frosting, and so on -the space of possible cakes shrinks until a single cake (the one you will actually bake) remains. In the same manner, any choice of neurobiological or behavioral hints to use in an artificial vision system constrains
